Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Evaluate the Phase I Pharmacokinetics of Anlotinib Hydrochloride Capsules in Liver Dysfunction Patients and Healthy Subjects

Next Previous
Trial Profile

To Evaluate the Phase I Pharmacokinetics of Anlotinib Hydrochloride Capsules in Liver Dysfunction Patients and Healthy Subjects

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary)
  • Indications Acral lentiginous melanoma; Alveolar soft part sarcoma; Bone cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Gastric cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Leiomyosarcoma; Liver cancer; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Synovial sarcoma; Thyroid cancer; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 04 Oct 2022 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top